Edward Miller, MD
Nuclear Cardiology · New Haven, CTNPI 1366617458
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (56.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 81.1% of it on its own, with 4 other manufacturers making up the rest. 2024 is the largest year on record at $20,000, 6.1 times the $3,269 reported in 2019.
Across 8 payments — averaging $4459.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$29K
- CSL Behring$3K
- Bracco Diagnostics Inc.$3K
- Akcea Therapeutics, Inc.$121
- Alnylam Pharmaceuticals Inc.$68
Across 48 payments — averaging $12,588 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$357K
- GE HealthCare$127K
- Siemens Medical Solutions USA, Inc.$99K
- Bracco Diagnostics Inc.$21K
What the payments were for
- Consulting fees$3,39510%
- Speaking & faculty fees$10,15228%
- Grants$20,00056%
- Travel & lodging$1,9385%
- Food & beverage$1901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 4 | $28,942 |
| CSL Behring | 1 | $3,395 |
| Bracco Diagnostics Inc. | 1 | $3,148 |
| Akcea Therapeutics, Inc. | 1 | $121 |
| Alnylam Pharmaceuticals Inc. | 1 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few nuclear cardiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 518 | $13,407,803 |
| VyndaqelTafamidis Meglumine | 135 | $3,066,295 |
| EliquisApixaban | 41 | $51,721 |
| FarxigaDapagliflozin Propanediol | 12 | $10,484 |
| BrilintaTicagrelor | 12 | $5,250 |
| Rosuvastatin Calcium | 18 | $430 |
| MethotrexateMethotrexate Sodium | 19 | $353 |
| SotalolSotalol Hcl | 12 | $345 |
| Spironolactone | 44 | $308 |
| Prednisone | 13 | $289 |
| Furosemide | 29 | $197 |
| Metoprolol Succinate | 20 | $165 |
| Carvedilol | 11 | $48 |
| Atorvastatin Calcium | 14 | $16 |
| Losartan Potassium | 15 | $6 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $28,942 | $16,525,820694 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other nuclear cardiology in New Haven
- Rahul GuptaNew Haven$24K
- Sanjeev BhavnaniHartford$29K
- Gary HellerHartford$11K
- William DuvallHartford$10K
- Adam SchussheimFairfield$10K
- Vinay GulatiHartford$8K
- Mehran SadeghiWest Haven$101
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.